|
10 April 2009 A divorce case was all that passed
for excitement at Richard P Altschuler's "kinda small"
lawyer's office in West Haven, Connecticut, when the
phone rang nine years ago. On the other end of the
line, a world away in the heat of Nigeria, was Etigwe
Uwo, a young lawyer with "an incredible story about
Pfizer". The Lagos attorney was going to take on the
largest pharmaceutical company in the world in an
unprecedented class action pitting African parents
against an American corporate giant. And he needed
help.
Mr Etigwe had chosen Mr Altschuler because, back in
1979, the Connecticut lawyer had successfully defended
a friend of the Nigerian. The unlikely pair were about
to embark on a marathon journey into the world of "big
pharma". Nine years on and their efforts have finally
been rewarded with a reported $75m (£50m) settlement,
the terms of which are likely to be released this
week.
If it sounds like the script of a Hollywood
blockbuster that's because it was this story that
prompted John Le Carre to write The Constant Gardener,
according to Mr Altschuler.
In real life it was to Nigeria, not Kenya, that Pfizer
turned. In 1996, the company needed a human trial for
what it hoped would be a pharmaceutical "blockbuster",
a broad spectrum antibiotic that could be taken in
tablet form. The US-based company sent a team of its
doctors into the Nigerian slum city of Kano in the
midst of an appaling meningitis epidemic to perform
what it calls a "humanitarian mission". However the
accusers claim it was an unlicensed medical trial on
critically-ill children.
A team of Pfizer doctors reached the Nigerian camp
just as the outbreak, which killed at least 11,000
people, was peaking. They set themselves up within
metres of a medical station run by the aid group
Médecins Sans Frontières, which was dispensing proven
treatments to ease the epidemic.
From the crowd that had gathered at the Kano
Infectious Diseases Hospital, 200 sick children were
picked. Half were given doses of the experimental
Pfizer drug called Trovan and the others were treated
with a proven antibiotic from a rival company.
Eleven of the children died and many more, it is
alleged, later suffered serious side-effects ranging
from organ failure to brain damage. But with
meningitis, cholera and measles still raging and
crowds still queueing at the fence of the camp, the
Pfizer team packed up after two weeks and left.
That would probably have been an end to the story if
it weren't for Pfizer employee, Juan Walterspiel.
About 18 months after the medical trial he wrote a
letter to the then chief executive of the company,
William Steere, saying that the trial had "violated
ethical rules". Mr Walterspiel was fired a day later
for reasons "unrelated" to the letter, insists Pfizer.
The company claims only five children died after
taking Trovan and six died after receiving injections
of the certified drug Rocephin. The pharmaceutical
giant says it was the meningitis that harmed the
children and not their drug trial. But did the parents
know that they were offering their children up for an
experimental medical trial?
"No," Nigerian parent Malam Musa Zango said. He claims
his son Sumaila, who was then 12 years old, was left
deaf and mute after taking part in the trial. But
Pfizer has denied this and says consent had been given
by the Nigerian state and the families of those
treated. It produced a letter of permission from a
Kano ethics committee. The letter turned out to have
been backdated and the committee set up a year after
the original medical trial.
At stake at one point last year was more than $8bn in
punitive damages being sought in a string of cases, as
well as potential jail terms in Nigeria for several
Pfizer staff. "There has been a complex web of cases
with proceedings in Connecticut, New York, Lagos,
Abuja and Kano," Mr Etigwe said. "The strategy of big
companies when they are dealing with smaller opponents
is to stretch the process, to overwhelm us until we
are ready to accept whatever they want to offer."
Trovan never became the blockbuster that Pfizer had
hoped for and it is no longer in production. The EU
has banned the drug and it has been withdrawn from
sale in the US.
It appears that Pfizer has finally ended the public
relations nightmare with Friday's settlement. But the
Trovan battle may not be over yet.
At the end of January 2009, a New York appeal court
ruled Mr Etigwe and Mr Altschuler's case could be
heard in the US. The Connecticut attorney says it
could still go ahead. "Our case is firmly embedded in
the US ... so a Nigerian settlement does not foreclose
our case. But this is very good news. I'm glad we
remained the constant gardener and could see this come
to fruition." |